Thematische Bibliographien / Ruiling Feng

Inhaltsverzeichnis

  1. Zeitschriftenartikel

Auswahl der wissenschaftlichen Literatur zum Thema „Ruiling Feng“

Autor: Grafiati
Veröffentlicht am 7. Juni 2025
Zuletzt aktualisiert am 2. August 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Ruiling Feng" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Ruiling Feng"

1

Gardner, Natalie, and Lanie Faust. "Automated written corrective feedback in research paper revision: The good, the bad, and the missing, by Qian Guo, Ruiling Feng, Yuanfang Hua." Feedback Research in Second Language 02 (June 2024): 81–85. https://doi.org/10.32038/frsl.2024.02.05.

Der volle Inhalt der Quelle
Annotation:
L2 graduate students face the dual struggles of being both second-language speakers and novice research writers. Publication is an important indicator of one’s academic potential, but the language barrier and a lack of research-writing experience often hinders L2 students’ ability to get published. In Automated Written Corrective Feedback in Research Paper Revision, Qian Guo, Ruiling Feng, and Yuanfang Hua show the potential AWE systems have to help L2 students overcome these barriers to publication. The authors study the usage of automated writing evaluation (AWE) systems in the context of re
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Zhu, Chaodong, Arong Luo, Ming Bai, et al. "A joint call for actions to advance taxonomy in China." Zoological Systematics 47, no. 3 (2022): 188–97. https://doi.org/10.11865/zs.2022302.

Der volle Inhalt der Quelle
Annotation:
Zhu, Chaodong, Luo, Arong, Bai, Ming, Orr, Michael C., Hou, Zhonge, Ge, Siqin, Chen, Jun, Hu, Yibo, Zhou, Xuming, Qiao, Gexia, Kong, Hongzhi, Lu, Limin, Jin, Xiaohua, Cai, Lei, Wei, Xinli, Zhao, Ruilin, Miao, Wei, Wang, Qingfeng, Sha, Zhongli, Lin, Qiang, Qu, Meng, Jiang, Jianping, Li, Jiatang, Che, Jing, Jiang, Xuelong, Chen, Xiaoyong, Gao, Lianming, Ren, Zongxin, Xiang, Chunlei, Luo, Shixiao, Wu, Donghui, Liu, Dong, Peng, Yanqiong, Su, Tao, Cai, Chenyang, Zhu, Tianqi, Cai, Wanzhi, Liu, Xingyue, Li, Hu, Xue, Huaijun, Ye, Zhen, Chen, Xuexin, Tang, Pu, Wei, Shujun, Pang, Hong, Xie, Qiang, Zhang
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Li, Yi, Xiaolei Qiu, Liping Feng, Dongxiao Feng, and Ruilin Sun. "Abstract 7011: Humanized CRBN knockin mice enable in vivo assessment the efficacy and toxicity of CRBN-targeted protein degraders." Cancer Research 85, no. 8_Supplement_1 (2025): 7011. https://doi.org/10.1158/1538-7445.am2025-7011.

Der volle Inhalt der Quelle
Annotation:
Abstract Protein degraders have emerged as a transformative therapeutic approach in the past decade, enabling targeted degradation of proteins, including traditionally undruggable targets, by facilitating the recruitment of E3 ubiquitin ligases. Among these, molecular glues such as thalidomide and its derivatives, and PROteolysis TArgeting Chimeras (PROTACs), have gained significant attention. Cereblon (CRBN), a key component of the Cullin 4 RING E3 ubiquitin ligase (CRL4), is the most extensively studied target in protein degrader research. CRBN interacts with DDB1, Cullin 4 (CUL4A/B), and RB
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Zhang, Yanlei, Hechun Ma, Boang Han, et al. "Abstract 2666: Genetic ablation of B2M leads to resistance to PD-1/PD-L1 blockade in vivo." Cancer Research 84, no. 6_Supplement (2024): 2666. http://dx.doi.org/10.1158/1538-7445.am2024-2666.

Der volle Inhalt der Quelle
Annotation:
Abstract Immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of various cancers by reinvigorating the exhausted T cells in patients. However, the therapeutic efficacy is largely confined due to the primary or acquired resistance to anti-PD-1 (L1) therapy in many patients. Recently, the mechanisms of resistance to ICIs has been extensively elucidated from different aspects and emerging sequencing data from clinical samples has pointed to IFN-γ signaling defects and antigen presentation loss in patients who are resistant to PD-1(L1) blockade. The loss-of-function mutat
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Li, Yi, Yanlei Zhang, Xiaolei Qiu, Dongxiao Feng, Ruilin Sun, and Daniel X. He. "Abstract 3739: Different combination regimens for OX40 agonists and PD-1 inhibitors exert different antitumor effects in OX40 humanized mice." Cancer Research 84, no. 6_Supplement (2024): 3739. http://dx.doi.org/10.1158/1538-7445.am2024-3739.

Der volle Inhalt der Quelle
Annotation:
Abstract OX40, also known as CD134 or TNFRSF4, is a member of the tumor necrosis factor receptor (TNFR) superfamily which mainly expressed on the surface of activated T cells including Treg cells. Engagement of OX40 with its ligand, TNFSF4, leads to effector T cell expansion and cytokine release, inhibits activation-induced cell death (AICD) and promotes the survival of antigen-specific memory T cells. In contrast to the massive hit of immune checkpoint inhibitors like PD-1 and PD-L1, the benefit of agonistic antibodies in clinical trials has not been completely demonstrated to date. On one ha
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Cheng, Ying, Lin Wu, Yong Fang, et al. "Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial." Cancer Research 84, no. 7_Supplement (2024): CT248. http://dx.doi.org/10.1158/1538-7445.am2024-ct248.

Der volle Inhalt der Quelle
Annotation:
Abstract Background: In China, non-approved therapies are used for pts with HER2 (ERBB2) mutant (HER2m) NSCLC. In DESTINY-Lung02 (DL-02), T-DXd 5.4 mg/kg showed clinical benefit with an acceptable and manageable safety profile in pts with pretreated HER2m metastatic NSCLC. DL-02 did not include any Chinese pts. We report the primary analysis of T-DXd in Chinese pts with pretreated HER2m metastatic NSCLC. Methods: In this open-label, single-arm, Phase 2 trial (NCT05246514), Chinese pts with HER2m (locally or centrally confirmed activating HER2 exon 19 or 20 mutation) metastatic non-squamous NSC
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Mai, Hai-Qiang, Qiu-Yan Chen, Dongping Chen, et al. "Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma." Cancer Research 82, no. 12_Supplement (2022): CT226. http://dx.doi.org/10.1158/1538-7445.am2022-ct226.

Der volle Inhalt der Quelle
Annotation:
Abstract Background: Gemcitabine-Cisplatin (GP) chemotherapy is the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab, a humanized IgG4K monoclonal antibody specific for PD-1, in combination with GP chemotherapy showed significant improvement in progression-free survival (PFS) as first-line treatment for RM-NPC at the interim analysis of the JUPITER-02 study (NCT03581786), a randomized, placebo-controlled, double-blinded international Phase III trial. Here we report the results of the final PFS analysis and the interim overall survival (OS
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Zafar, Imran. "Early Detection and Analysis of Accurate Breast Cancer for Improved Diagnosis Using Deep Supervised Learning for Enhanced Patient Outcomes." PeerJ Computer Science, March 15, 2025. https://doi.org/10.5281/zenodo.15032559.

Der volle Inhalt der Quelle
Annotation:
Early detection of breast cancer (BC) is essential for effective treatment and improved diagnosis. This study compares the performance of various machine learning (ML) algorithms, including convolutional neural networks (CNNs), logistic regression (LR), support vector machines (SVMs), and Gaussian naive Bayes (GNB), on two key datasets, Wisconsin Diagnostic Breast Cancer (WDBC) and Breast Cancer Histopathological Image Classification (BreaKHis). For the BreaKHis dataset, the CNN achieved an impressive accuracy of 92%, with precision, recall, and F1 score values of 91%, 93%, and 91%, respective
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie